In Nov. 2022, the U.S. nonprofit Multidisciplinary Affiliation for Psychedelic scientific studies (MAPS) declared that it experienced completed a second phase-3 trial on MDMA as a treatment for PTSD—a step extensively https://psychedelicmushroomstores.com/product-category/mushroom-edibles-for-sale/